These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28591695)

  • 1. Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports.
    Liu Y; Zhang Y; Zhang L; Liu B; Wang Y; Zhou X; Li Y; Zhao Q; Gong Y; Zhou L; Zhu J; Ding Z; Wang J; Peng F; Huang M; Li L; Ren L; Lu Y
    Oncotarget; 2017 Jul; 8(30):49680-49688. PubMed ID: 28591695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comprehensive Review of Epidermal Growth Factor Receptor Mutation Abundance in Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.
    Zeng L; Dai Y; Liu Y; Song B; Lin H; Xiao J
    Oncol Res Treat; 2024; 47(12):602-609. PubMed ID: 39353410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac Events and Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer Treated With Osimertinib.
    Lin CY; Chang WT; Su PL; Kuo CW; Yang J; Lin CC; Lin SH
    JAMA Netw Open; 2024 Dec; 7(12):e2448364. PubMed ID: 39636639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients.
    Wang C; Zhao K; Hu S; Dong W; Gong Y; Li M; Xie C
    Lung Cancer; 2022 Oct; 172():86-93. PubMed ID: 36027855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Zer A; Ding K; Lee SM; Goss GD; Seymour L; Ellis PM; Hackshaw A; Bradbury PA; Han L; O'Callaghan CJ; Tsao MS; Shepherd FA
    J Thorac Oncol; 2016 Mar; 11(3):312-23. PubMed ID: 26749487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
    Takeda M; Okamoto I; Nakagawa K
    Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01.
    Hibino M; Imamura Y; Shimoyama R; Fukui T; Fukai R; Iwase A; Tamura Y; Chihara Y; Okabe T; Uryu K; Okuda T; Taguri M; Minami H
    Target Oncol; 2024 Nov; 19(6):925-939. PubMed ID: 39302602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the optimal first-line regimen for advanced non-small cell lung cancer patients with epidermal growth factor receptor mutation: a systematic review and network meta-analysis.
    Zhang W; Zhang X; Zhao W; Guo Z; Liu X; Ye L; Chen Z; Xu K; Liu Y; Wang H; Zhao L; Zhang Q; Li Y; Chen X; He Y
    BMC Pulm Med; 2024 Dec; 24(1):620. PubMed ID: 39695621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.
    Costa DB; Kobayashi S; Tenen DG; Huberman MS
    Lung Cancer; 2007 Oct; 58(1):95-103. PubMed ID: 17610986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploration of efficacy of the first-line treatment for advanced non-small cell lung cancer with primary MET-amplification: Retrospective evaluation of 36 cases.
    Ding K; Liu D; Jin X; Xu Y
    Int Immunopharmacol; 2024 Dec; 143(Pt 2):113391. PubMed ID: 39427497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients: Pooled analysis and subgroup analysis of efficacy and safety.
    Xu R; Shao H; Zhu J; Ju Q; Shi H
    Medicine (Baltimore); 2019 Mar; 98(13):e14135. PubMed ID: 30921175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy.
    Saalfeld FC; Möller J; Christopoulos P; Wenzel C; Rasokat A; Wang XA; Vathiotis I; König D; Illini O; Grohé C; Wiesweg M; Wesseler C; Schubart C; Pelusi N; Rohde G; Overbeck TR; Kirfel J; Alt J; Kauffmann-Guerrero D; Griesinger F; Kulhavy J; Allgäuer M; Klimova A; Schütz M; Aust DE; Hochmair MJ; Rothschild SI; Syrigos KN; Veluswamy R; Michels S; Stenzinger A; Jöhrens K; Wermke M
    Eur J Cancer; 2024 Dec; 213():115065. PubMed ID: 39423775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.
    Han JY; Ahn MJ; Lee KH; Lee YG; Kim DW; Min YJ; Kim SW; Cho EK; Kim JH; Lee GW; Lee SS; Lee NM; Jang HW; Han H; Park H; Lee J; Cho BC
    BMC Med; 2024 Oct; 22(1):428. PubMed ID: 39379931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of direct bilirubin and total bile acid in lung adenocarcinoma patients treated with EGFR-TKIs.
    Li Y; Wang B; Fei S; Qin Y
    BMC Pulm Med; 2024 Nov; 24(1):583. PubMed ID: 39580432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.
    Kraskowski O; Stratmann JA; Wiesweg M; Eberhardt W; Metzenmacher M; Schmid KW; Herold T; Schildhaus HU; Darwiche K; Aigner C; Stuschke M; Laue K; Zaun G; Kasper S; Hense J; Sebastian M; Schuler M; Pogorzelski M
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9243-9252. PubMed ID: 37198447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.
    Yang S; Wu S; Zhao Y; Chen G; Zhu B; Li X; Wang K; Shi J; Cang S; Yao W; Fan Y; Fang J; Zhang L; Zhou J; Wu L; Zheng R; Huang M; Pan Y; Yang Z; Sun M; Yu H; Wang D; Huang J; Wang L; Shu Y; Chen Z; Liu C; Li J; Liu J; Sun S; Guo Y; Meng Z; Liu Z; Han Z; Wu G; Lu H; Ma R; Hu S; Zhao G; Zhang L; Liu Z; Xie C; Zhong D; Zhao H; Bi M; Yi S; Guo S; Yi T; Li W; Lin Y; Chen Z; Zhuang Z; Guo Z; Greco M; Wang T; Zhou A; Shi Y
    Lung Cancer; 2023 Jun; 180():107194. PubMed ID: 37163774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis.
    Wang C; Zhao K; Hu S; Dong W; Gong Y; Xie C
    Oncologist; 2023 Jun; 28(6):e397-e405. PubMed ID: 37116899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.